Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:893-899
doi: 10.1161/CIRCULATIONAHA.104.521344
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deguchi, H.
Right arrow Articles by Griffin, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deguchi, H.
Right arrow Articles by Griffin, J. H.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Deep vein thrombosis
Right arrow Lipid and lipoprotein metabolism

(Circulation. 2005;112:893-899.)
© 2005 American Heart Association, Inc.


Vascular Medicine

High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men

Hiroshi Deguchi, MD, PhD; Natalie M. Pecheniuk, PhD; Darlene J. Elias, MD; Patricia M. Averell, BSN; John H. Griffin, PhD

From the Department of Molecular and Experimental Medicine, The Scripps Research Institute (H.D., N.M.P., D.J.E., J.H.G.), and the Division of Chest and Critical Care Medicine, Department of Medicine, Scripps Clinic (D.J.E., P.M.A.), La Jolla, Calif.

Correspondence to John H. Griffin, PhD, Department of Molecular and Experimental Medicine (MEM-180), The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037. E-mail jgriffin{at}scripps.edu

Received November 17, 2004; revision received March 31, 2005; accepted April 26, 2005.

Background— Although dyslipoproteinemia is associated with arterial atherothrombosis, little is known about plasma lipoproteins in venous thrombosis patients.

Methods and Results— We determined plasma lipoprotein subclass concentrations using nuclear magnetic resonance spectroscopy and antigenic levels of apolipoproteins AI and B in blood samples from 49 male venous thrombosis patients and matched controls aged <55 years. Venous thrombosis patients had significantly lower levels of HDL particles, large HDL particles, HDL cholesterol, and apolipoprotein AI and significantly higher levels of LDL particles and small LDL particles. The quartile-based odds ratios for decreased HDL particle and apolipoprotein AI levels in patients compared with controls were 6.5 and 6.0 (95% CI, 2.3 to 19 and 2.1 to 17), respectively. Odds ratios for apolipoprotein B/apolipoprotein AI ratio and LDL cholesterol/HDL cholesterol ratio were 6.3 and 2.7 (95% CI, 1.9 to 21 and 1.1 to 6.5), respectively. When polymorphisms in genes for hepatic lipase, endothelial lipase, and cholesteryl ester transfer protein were analyzed, patients differed significantly from controls in the allelic frequency for the TaqI B1/B2 polymorphism in cholesteryl ester transfer protein, consistent with the observed pattern of lower HDL and higher LDL.

Conclusions— Venous thrombosis in men aged <55 years old is associated with dyslipoproteinemia involving lower levels of HDL particles, elevated levels of small LDL particles, and an elevated ratio of apolipoprotein B/apolipoprotein AI. This dyslipoproteinemia seems associated with a related cholesteryl ester transfer protein genotype difference.


Key Words: lipoproteins • men • risk factors • thrombosis




This article has been cited by other articles:


Home page
JAMAHome page
A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
JAMA, June 18, 2008; 299(23): 2777 - 2788.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
D J Hausenloy and D M Yellon
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Heart, June 1, 2008; 94(6): 706 - 714.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Ageno, C. Becattini, T. Brighton, R. Selby, and P. W. Kamphuisen
Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis
Circulation, January 1, 2008; 117(1): 93 - 102.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Eichinger, N. M. Pecheniuk, G. Hron, H. Deguchi, M. Schemper, P. A. Kyrle, and J. H. Griffin
High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism
Circulation, March 27, 2007; 115(12): 1609 - 1614.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
C. Ay, T. Tengler, R. Vormittag, R. Simanek, W. Dorda, T. Vukovich, and I. Pabinger
Venous thromboembolism a manifestation of the metabolic syndrome
Haematologica, March 1, 2007; 92(3): 374 - 380.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Mineo, H. Deguchi, J. H. Griffin, and P. W. Shaul
Endothelial and Antithrombotic Actions of HDL
Circ. Res., June 9, 2006; 98(11): 1352 - 1364.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. D. Otvos, D. Collins, D. S. Freedman, I. Shalaurova, E. J. Schaefer, J. R. McNamara, H. E. Bloomfield, and S. J. Robins
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
Circulation, March 28, 2006; 113(12): 1556 - 1563.
[Abstract] [Full Text] [PDF]